RT Journal Article
SR Electronic
T1 Determinants of Post-acute COVID-19 Syndrome among hospitalized severe COVID-19 patients: a 2-year follow up study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.13.23290674
DO 10.1101/2023.06.13.23290674
A1 Elias, Tamrat P.
A1 Gebreamlak, Tsegaye W.
A1 Gebremeskel, Tigist T.
A1 Adde, Binyam L.
A1 Elias, Bitaniya P.
A1 Argaw, Abel M.
A1 Tenaw, Addis A.
YR 2023
UL http://medrxiv.org/content/early/2023/06/16/2023.06.13.23290674.abstract
AB Background Coronavirus disease-19 (COVID-19), emerged as a public health threat in December 2019. The number of COVID-19 cases worldwide is now more than 765 million with more than 6.9 million dead. During follow-up visits following discharge, a large percentage of patients were discovered to still be suffering from health issues that lower their quality of life and ability to return to work. This study assessed the prevalence and associated risk factors of post-acute COVID-19 syndrome (PACS) among severe COVID-19 patients who were discharged from Millennium COVID-19 care center, Addis Ababa, Ethiopia.Methods A cross-sectional study using data collected from patient charts and a follow-up telephone interview after two years of discharge. Systematic random samplingwas used to select a total of 400 patients. A structured questionnaire developed from the case report form for PACS of WHO was used. Frequency and cross-tabulation were used for descriptive statistics. Predictor variables with a p-value <0.25 in bivariate analyses were included in the logistic regression.Result Out of the 400 patients, 20 patients were dead, 14 patients refused to give consent, and 26 patients couldn’t be reached because their phone wasn’t working. Finally, 340 were included in the study. The majority (68.5%) were males and the mean age was 53.9 (±13.3 SD) years. Most of the patients (60%) has one or more comorbidity. The most common symptom at presentation was cough (93.5%), followed by shortness of breath (82.1%) and fatigue (69.7%). The mean duration of hospital admission was 12.3 (±6.5 SD) days. More than a third (38.1%) of the patients reported the persistence of at least one symptom after hospital discharge. The most common symptoms were fatigue (27.5%) and Cough (15.3%). older age (AOR 1.04, 95% CI 1.02 – 1.07), female sex (AOR 1.82, 95% CI 1.00 – 3.29), presence of comorbidity (AOR 2.38, 95% CI 1.35 – 4.19), alcohol use (AOR 3.05, 95% CI 1.49 – 6.26), fatigue at presentation (AOR 2.18, 95% CI 1.21 – 3.95), and longer hospital stay (AOR 1.06, 95% CI 1.02 – 1.10) were found to increase the odds of developing post-acute COVID-19 syndrome. Higher hemoglobin level was found to decrease the risk of subsequent post-acute COVID-19 syndrome (AOR 0.84, 95% CI 0.71 – 0.99).Conclusion establishing a dedicated PACS follow-up clinic, especially for those with a higher risk can help to provide comprehensive care for the patients and improve their quality of life.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of St. Paul's hospital millennium medical college gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.